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Since the prequalification of the Typhoid conjugate vaccine
(TCV) by the WHO and subsequent position paper published in
2018, strategies for roll-out of the vaccine have been under discus-
sion [1]. The 2018 position paper recommends the introduction of
TCV to be prioritized in countries with the highest burden of
typhoid disease or a high burden of antimicrobial resistant S. Typhi
[1]. The paper further suggests that ‘‘Decisions on the age of TCV
administration, target population and delivery strategy for routine
and catch-up vaccination should be based on the local epidemiol-
ogy of typhoid fever. . .”. However, local epidemiology of typhoid
fever is often poorly documented, due to the paucity of diagnostic
facilities in many high typhoid incidence settings. However, most
low- and middle income- countries (LMIC) rely on ad hoc reporting
of typhoid fever, and very few have data frommore than one city in
the country. There have been substantial efforts aimed at strength-
ening blood culture surveillance for typhoid fever in Africa [2], yet
there are still only 13 sentinel sites in 10 countries; a similar initia-
tive in Asia covers only four countries [3]. Data sets that are uti-
lized to estimate global burden are therefore limited by the lack
of surveillance [4–7]. Based on the prohibitive costs [2] and efforts
required to strengthen blood culture surveillance in LMIC, expan-
sion of these efforts to capture both national and sub-national
trends of typhoid on a global scale are not likely on a time scale rel-
evant to vaccine roll-out.
Incidence mapping using statistical models can aid in predicting
incidence in areas without surveillance, using spatial covariates
relevant to risk of disease, and has been used for diseases such as
malaria [8]. This approach has been attempted for typhoid through
global burden models [4], but out-of-sample validation, though
accurate in some areas, was not reliable, indicating a lack of usefulindicators that can be consistently used to predict typhoid inci-
dence. Further, the current breadth of data is heavily biased by
reporting from a handful of well-funded sites, so predicting sub-
national incidence across large regions is a challenge. A country’s
ability to roll out TCV in accordance with the WHO’s position paper
is therefore hindered by a lack of knowledge of local epidemiology
of the disease. Additionally, Gavi, The Vaccine Alliance, recom-
mends that countries requesting TCV funding should submit epi-
demiological data from within-country whenever possible,
though this is not strictly a requirement.
Alternative tools are needed for planning TCV strategies in the
absence of blood culture surveillance. Of particular interest is envi-
ronmental surveillance,where, insteadof relyingonclinical detection
of the disease, catchments in the environment such as water or sew-
age systems are surveilled. This approach has been successfully used
in thepolio eradication campaign. [9] Thoughcase-based surveillance
for polio is widespread, the disease is known to undergo sub-clinical
(silent) transmission. ES has enabled detection when there is not a
knownoutbreakandhasbeendemonstrated tobe auseful tool inpro-
gram decisionmaking [10,11]. Since typhoid and polio share similar-
itieswith regards to transmission routes and sub-clinical disease, it is
possible that the approach and the network of laboratories developed
for polio could be adapted for typhoid.
There remain significant technical challenges to implementing
typhoid environmental surveillance (ES); optimal sampling strate-
gies and detection methods, and their reliability as an indicator of
ongoing transmission, remain unclear. Historically, Moore swabs
have been used to isolate S. Typhi from sewage [12,13], however
present day ES initiatives have been more focused on molecular
approaches, specifically polymerase chain reaction (PCR)-based
detection of S Typhi [14–16].
Economic analyses have largely supported the cost-effectiveness
of the roll out of TCV in high and medium- incidence areas, particu-
larly when routine vaccination strategies are paired with catch-up
campaigns [17,18], however, there is more uncertainty aroundyphoid
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examine the use of a hypothetical environmental surveillance pro-
gram as a method for quickly gathering evidence on which an intro-
duction decision can be based. This is especially relevant in places
where there are inadequate burden estimates or in which a national
introduction may not be affordable due to funding constraints or
competing priorities. Specifically, we evaluate the value of environ-
mental sampling as a means of detecting circulating typhoid in
order to guide local or national targeting of catch-up vaccination
campaigns. We aim to determine the most cost-effective sampling
and roll-out strategies, given the limited information and substantial
uncertainty about the true underlying prevalence of typhoid.
2. Methods
This was a simulation study with an integrated epidemiological
and economic model, which was used to evaluate the cost-
effectiveness of surveillance and vaccination strategies.Fig. 1. A. Disease transmission model structure. B. HINT s
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Disease transmission mechanisms and individual-level immu-
nity were simulated using an individual-based mathematical
model, EMOD [20], with detailed model structure and assumptions
previously described [21], outlined in Fig. 1A, and included in the
supplement. Briefly, the model assumes typhoid fever infections
may be acute or subclinical after an incubation period, with a pro-
portion of cases becoming chronic carriers, which is assumed to be
a lifelong state. We simulate two distinct transmission routes,
short- and long-cycle. Short-cycle transmission represents infec-
tions acquired from food or water contaminated by an individual
in the immediate environment (i.e. household or school), while
long-cycle transmission indicates infections acquired from expo-
sure to S. Typhi in the environment, which could include drinking
contaminated water or exposure to sewage. Infectious individuals
shed into simulated composite of contaminated vehicles of trans-
mission, or CCVT, for each transmission route. The probability oftructure and environmental surveillance mechanism.
iveness of using environmental surveillance to target the roll-out typhoid
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exposures using population-scaled CCVT as a simulated ‘dose’
[22], while for the short-cycle, the probability of infection is calcu-
lated as the population-scaled short-cycle CCVT divided by the
total potential short-cycle CCVT. Long-cycle exposure is mediated
by seasonal attenuation, and we reduce proportion of children
born into the simulation who become susceptible- these parame-
ters are estimated through model fitting
One primary modification was made to the model for this study.
We adapted the model to allow us to divide the simulated popula-
tion into pre-specified transmission groups, referred to as hetero-
geneous intra-node transmission (HINT) groups (Fig. 1B).
Transmission rates within and between HINT groups can be mod-
ified, with within-HINT transmission altered as a multiplier on
both the long- and short-cycle CCVT. We utilized this feature to
simulate a heterogenous disease landscape within a single simula-
tion model. When we attempt to represent typhoid transmission
over a large geographic region, HINT groups represent
epidemiologically-relevant areas within which transmission is
assumed to be consistent. For example, a HINT group could repre-
sent a city or a state that contains one set of transmission dynamics
but may have distinct characteristics compared to a neighboring
population. We refer to these as transmission locales.
2.2. Disease transmission model fitting
We aimed to fit our model to represent transmission of typhoid
fever in Malawi. A single reporting hospital in Blantyre, Malawi,
maintains blood culture surveillance for typhoid fever [22], and
we used data from both inpatients and outpatients in this surveil-
lance system to fit our model. Typhoid incidence outside of Blan-
tyre is not well characterized. Given the limited data, we divided
the country into five transmission locales. Although there is likely
a gradient of transmission that exists across Malawi, we represent
transmission using two possible landscapes representing endemic
and low transmission, based on economic analyses which have
identified low incidence settings as a lower bound of cost-
effectiveness of the vaccine [17]. We fit endemic locales to the
annual unadjusted incidence rates, age distribution, and seasonal-
ity of reported typhoid fever in Blantyre from 2015 to 2016, while
the low transmission locales were fit to the annual unadjusted inci-
dence rates of typhoid in Blantyre between 1998 and 2010. Risk of
exposure in the model does not include migration between trans-
mission locales, which allows us to maintain heterogeneity of the
incidence landscape over time. Further detail on the model struc-
ture and fitting are included in the supplement.
2.3. Environmental surveillance framework
We added an environmental surveillance (ES) diagnostic feature
to the mathematical model for the purposes of this analysis. This
was a hypothetical automated and responsive tool that tracks the
simulated environmental CCVT for each transmission locale.
The development of an environmental sampling method is still
ongoing. For these purposes, we work on the premise that a test
that was accepted by the public health community for wide
deployment would be reliable and would concentrate fecal matter
from the environment into a manageable sample. We assume that
sites selected for ES would be representative of the catchment area.
We selected a threshold of CCVT for a detection ‘‘positive” that
reflected underlying endemicity in the simulation. We first applied
a test sensitivity (85%) and specificity rate (80%) that create uncer-
tainty of whether the diagnostic would signal correctly in the sim-
ulation. We additionally modified the portion of individuals in a
given locale that are sampled by the environmental diagnostic
(80%); in the real world, an ES system could never cover all possiblePlease cite this article as: B. L. Hagedorn, J. Gauld, N. Feasey et al., Cost-effect
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baseline, we assume that samples are taken weekly for a year, prior
to any decision about vaccination being made. We assume that at
least one third of the year’s samples would need to be positive
before a decision maker would be willing to conclude that typhoid
is indeed endemic in their area. This is likely a high threshold for
positive responses given real-world detection rates in known
chronic carriers to be only 25%, as reported in Santiago, Chile using
Moore swabs [23].
We tested the robustness of the results by varying the hetero-
geneity in the incidence landscape and surveillance coverage. We
did so by sweeping the proportion of transmission locales that
are endemic, between 1 and 5 of 5, with the remaining set to
low transmission. We also varied the proportion of transmission
locales sampled by the ES system, from 1 to 5 of 5.
2.4. Vaccination decisions
We assumed that routine immunization (RI) would be rolled
out for all children at 9 months of age, consistent with the existing
EPI schedule for measles-containing vaccine, as recommended by
the WHO [19,20]. This was implemented simultaneously with
the beginning of any ES-derived catch-up campaign, as is under
consideration for funding by Gavi, the Vaccine Alliance in eligible
countries [26]. We assumed that any catch-up campaign would
reach 85% of the target population aged 9 months-15 years and
vaccine efficacy was set at 87% based on the clinical protection
estimated in challenge models [27].
We explored policy frameworks to decide whether and where
to do a catch-up vaccination campaign in response to the ES
results. Catch-up campaigns were responsive to the environmental
surveillance system, and two primary strategies were explored. In
some scenarios, a country may decide to implement a national
catch-up vaccination campaign after detection in a major city or
sentinel site. Others may decide to only implement localized
catch-up vaccination in areas that are considered high risk due to
likely endemic transmission (as detected by ES sampling). These
are referred to as national and local (sub-national) catch-up cam-
paign strategies.
2.5. Economic model
The economic model took two perspectives: programmatic and
health system.
The programmatic perspective included the cost of vaccines and
supplies purchased, vaccination delivery, and environmental sam-
ple collection and testing. We varied the unit cost for vaccination
depending on the delivery method, since there are operational cost
differences between vaccines delivered via a supplementary
immunization activity (SIA) for a catch-up campaign versus rou-
tine immunization after the vaccine is added to the standard EPI
schedule. Syringe and waste boxes are procured in large volumes
by UNICEF to support multiple vaccines, so we did not simulate
uncertainty in their pricing. Wastage and transportation rates are
well established by Gavi, so we did not simulate uncertainty in
their levels.
For the health system perspective, we also included the cost of
treatment for both typical and multi-drug resistant typhoid cases,
direct non-medical costs, and lost wages (indirect costs) for inpa-
tient cases. Average treatment costs were calculated based on sep-
ticemia discharges reported at the Queen Elizabeth Central
Hospital in Malawi, adjusted for inflation from 2014 to 2018 US
dollars [28]. We used the average daily cost in US dollars for the
portion that was due to the ward stay to estimate the daily ward
cost and multiplied that with the typical length of stay for
hospital-treated cases. We included the average investigation andiveness of using environmental surveillance to target the roll-out typhoid
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(indirect) costs as well for inpatient cases. Finally, we calculated
the expected drug cost for uncomplicated (outpatient) typhoid
based on Medicines Sans Frontieres’s treatment guidelines for
low resource settings [29] and based on ceftriaxone plus seven
days of ciprofloxacin at 750 mg dosage for inpatient treatment
(as is currently done in Blantyre), using current UNICEF supply
prices [30]. MDR case treatment costs are higher than non-MDR
cases primarily due to more expensive drug costs.
We assessed the impact of stochastic variation in the model
parameters by using a Monte Carlo simulation to simultaneously
vary both the economic and epidemiological parameters. The
simulation sampled values for the unit costs for vaccines, vaccina-
tion delivery, and environmental sampling. Ranges for each param-
eter were simulated as triangular distributions, with 95% CI values
listed in Table 1. The model generated a stochastic economic model
estimate for each EMOD simulation. These results were used to cal-
culate the simulated 95th percentile simulated intervals for each
scenario, which are the result of both epidemiological and cost
uncertainty. In addition to the scenario comparison, which reflects
the unknowns about the true epidemiology of Malawi, we also
conducted a one-way sensitivity analysis on the cost model param-
eters in Table 1, varying each one independently from one half to
twice the expected value (maxing out at 100% where applicable),Table 1
Economic Model Parameters. Outpatient treatment costs include drug costs only. Inpatien
and lost wages (indirect) costs.
Parameter Value
Vaccine cost $1.50 per dose, 5-dose via
Syringe cost $0.04 per syringe, single u
Wastage box $0.45 per box, 100 capacit
Supply wastage rate 10%
Transportation cost 3% of vaccine cost
Vaccination delivery, SIA $0.74 per dose
Vaccination delivery, RI $0.59 per dose
Uncomplicated outpatient treatment (typical/MDR) $1.50 / $2.40
Inpatient treatment (all) $238.34
Portion of all cases that are uncomplicated (vs. severe) 90%
Portion of all cases that are multi-drug resistant 95%
Environmental sampling (PCR) $33.00 per sample
Discount rate (applied to both costs and cases) 3%
Table 2
Incremental cost-effectiveness ratios (ICER). The ICER table is sorted by the simulated av
incremental reduction in cases. Scenarios that are both more expensive and have higher
calculated. All costs reported in 2018 US dollars. ‘‘L# dominated” indicates that this line is an
it both costs more and has higher incidence than the reference line. NA = Not applicable,
table; the program and total costs are presented here for reader interest only.
Scenario # ES Locales Incidence per 100 k Avg. Program Cost
(1000s)
Avg. Tot
Baseline 0 101.33 $0.00 $13.3
RI Only 0 95.63 $52.3 $64.7
Local 1 81.59 $57.3 $68.1
Local 2 67.30 $62.2 $71.2
Local 3 52.95 $67.4 $74.4
National 1 39.69 $77.4 $82.8
Local 4 38.65 $72.5 $77.6
National 2 30.74 $84.1 $88.3
National 3 36.49 $88.5 $92.1
National 4 24.91 $91.1 $94.5
Local 5 24.65 $77.5 $80.7
National 5 23.95 $92.8 $96.1
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Aggregated cost and disease impacts were summarized using an
incremental cost-effectiveness ratio (ICER) by dividing the differ-
ence in total costs by the difference in the number of cases. Using
this method, any scenario for which there is an alternative scenario
that has fewer cases of typhoid and also lower costs is considered
‘‘dominated” and discarded as an alternative. The remaining
options are on the efficient frontier (aka. the most impact for the
dollar spent) and are compared. (Table 2).
We tested for statistically significant differences between
strategies and between levels of ES, for both costs and incidence.
These results by conducting a Welch 2-sample t-test for each pair-
ing and confirmed it by considering the non-parametric Wilcox
test as well, since the simulated results violate the equal variance
condition for the Welch test when comparing the baseline to
vaccination.3. Results
3.1. Simulation models were reliably fit to historical incidence
Estimated model parameters fitted well to age distribution, sea-
sonality, and incidence rate in endemic and low incidence trans-t treatment costs include investigation and procedure costs, direct non-medical costs,
Simulated Range References
l Fixed, negotiated prices [30]
se Fixed, negotiated prices [31]
y Fixed, negotiated prices [31]
Fixed, planning standard [32]







±50% Personal correspondence; cost in the
context of a mature laboratory
Standard economics assumption [36]
erage number of cases and then the ICER is calculated as the incremental cost per
number of cases than an alternative are considered dominated and the ICER is not
inferior option compared to the referenced line and is thus considered dominated, i.e.
as these are the baseline from which ICER is calculated for the remaining lines in the
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Fig. 2. Fitted parameters. A. Boxplots of incidence per 100,000 in the fitted model, with Blantyre data represented as a red point this example is for a scenario with 3 of 5
transmission locales set to endemic transmission. B. Fit of the endemic locales to observed seasonality. C. Fit of the endemic locales to observed age distribution of cases. (For
interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 3. Simulated disease incidence per 100,000 person-years. Each boxplot displays the typhoid case incidence per 100,000 person-years over ten simulated years. They
display the median as a central line in the box, which extends to the 1st and 3rd quartiles; the lines extend to the max and min, excepting outliers which are displayed as
points. Plot A displays the incidence level in baseline scenarios where there was no vaccination, broken out by the underlying disease incidence. Plots B and C summarize
results for simulations where 3 out of 5 simulated locales were endemic (2/5 had low incidence). Plot B compares the baseline incidence with routine immunization only and
ES-informed local (sub-national) and national catch-up campaigns. Plot C displays the results from catch-up campaigns that are informed by increasing levels of ES coverage
(i.e. the more surveillance, the more likely the simulation is to detect typhoid and vaccinate appropriately).
B.L. Hagedorn et al. / Vaccine xxx (xxxx) xxx 5mission time periods in Blantyre (Fig. 2). A summary of fitted
parameters is in Supplementary table S3.
The simulation model results were aggregated by scenario and
the resulting patterns in total incidence were as expected (Fig. 3).Please cite this article as: B. L. Hagedorn, J. Gauld, N. Feasey et al., Cost-effect
conjugate vaccine, Vaccine, https://doi.org/10.1016/j.vaccine.2019.12.061With higher endemicity (ranging from one to five endemic locales,
out of five total), we see increasing incidence in the total popula-
tion (Fig. 3A). The introduction of routine immunization only
(without a catch-up campaign) has a limited impact on incidenceiveness of using environmental surveillance to target the roll-out typhoid
6 B.L. Hagedorn et al. / Vaccine xxx (xxxx) xxx(Fig. 3B), due to the slow pace of vaccine-derived immunity. Since
routine immunization (RI) is only being provided to the birth
cohort as it reaches the age of 9 months, so we do not detect a large
impact in the total population’s incidence over our 10-year model.
The sub-national and national catch-up campaigns reduce
incidence, with the national campaigns suppressing disease fur-
ther, given that it is inherently a larger-scale vaccination program.
Additionally, we found that with increasing environmental surveil-
lance (ES) coverage, incidence was lower (Fig. 3C), reflecting our
ability to appropriately detect and respond to ongoing transmis-
sion with better ES coverage.
3.2. Over- and under-vaccination were both risks
The most optimal use of vaccine would be to vaccinate all of
(but only) the endemic locales. Since we hid the true endemicity
from our simulated decision making and only provided
ES-derived information, the campaign choices are frequently
sub-optimal in the simulation.
We considered any instance where a low-transmission
locale was vaccinated to be ‘‘non-endemic vaccination”. We
considered any instance where an endemic (high transmission)
locale was never vaccinated to be a ‘‘missed opportunity”, since
there were many cases that could have been prevented but
were not.
The national strategy, where all children are vaccinated based
on endemicity anywhere, resulted in high rates of non-endemic
vaccination. However, there are relatively few missed opportuni-
ties, especially when there are high levels of environmental
surveillance. In contrast, the local strategy, where children are vac-
cinated if and only if they live in a locale with detected endemicity,
resulted in high levels of missed opportunities, although these
decline considerably as ES coverage increases. Simultaneously,
there is low probability of non-endemic vaccination with a local
strategy, since it is unlikely that the environmental surveillance
diagnostic would generate enough false positives to trigger an
unneeded campaign (Fig. 4). Though the precise ES methodology
has yet to be recommended for typhoid, with PCRmethods, the riskFig. 4. Catch-up campaign precision. Impact of environmental surveillance levels on the
percentage of simulation runs in which either non-endemic vaccination or missed op
Simulations with optimally-targeted campaigns (i.e. when all endemic locales – and only
100%.
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tion work would be useful to explore these results across a range of
specificity values.
3.3. National catch-up campaigns reduced burden but cost more than
local campaigns
Total program costs include the cost of environmental surveil-
lance, routine vaccination, and catch-up campaigns. These are
exactly zero in the baseline scenario, are an average per capita of
$0.76 ($0.58, $1.00) for a local (sub-national) strategy and $1.00
($0.58, $1.15) for a national campaign strategy.
Total societal costs include program costs, plus the direct med-
ical treatment costs, direct non-medical costs, and the indirect lost
productivity costs for acute cases (Fig. 5). These are an average per
capita of $0.15 ($0.02, $1.41) in the baseline scenario, $0.85 ($0.63,
$1.12) for local (sub-national) strategies, and $1.04 ($0.63, $1.21)
for national strategies. Treatment is 100% of total societal costs
for baseline, 5% (1%, 17%) for national strategies, and 10% (1%,
27%) for local strategies.
Both local and national strategy costs are significantly more
than the baseline scenario and national strategies cost more than
local (p-values <0.001). Total costs were significantly higher as a
result of additional environmental surveillance for all comparisons
within local and within national strategies (p-values <0.01).
Both local and national strategy costs achieved lower incidence
than the baseline scenario (p-values <0.001) and national strate-
gies achieved lower incidence than local in aggregate (p-value
<0.001) (Fig. 4). Incidence rates were significantly lower as a result
of additional environmental surveillance for all comparisons (p-
values <0.01) except when comparing within national strategies
with 3–5 locales with ES (Fig. 5), though these were distinct from
strategies relying on either 1 or 2.
As endemicity increased, the national strategy converged to a
consistent outcome, regardless of the level of ES coverage
(Fig. 6). With high levels of transmission, the difference between
the (any) national and high coverage-ES local strategies became
relatively indistinguishable. ES provided the most benefit at lowsuccessful targeting of national vs. local vaccination strategies. The bars indicate the
portunities occurred, for a given national/local strategy and level of ES coverage.
endemic locales – are vaccinated) are not shown; as a result, the bars do not sum to
iveness of using environmental surveillance to target the roll-out typhoid
Fig. 6. Cost efficiency frontier. The simulated total cost per capita includes vaccination, environmental surveillance, and treatment costs for acute cases. The incidence rate is
calculated over ten years. Both values are discounted at a rate of three percent per year.
Fig. 5. Simulated incidence and total costs per capita. Each point represents the outcomes of a single simulation run. Simulations are color coded to differentiate by
vaccination strategy and level of environmental surveillance that was deployed in the modeled scenario. The leftmost panel represents the baseline status quo, where no
vaccination is performed. All values reported in 2018 US dollars.
B.L. Hagedorn et al. / Vaccine xxx (xxxx) xxx 7incidence scenarios, because a local strategy was able to detect and
target high risk locales with catch-up vaccination. (Fig. 6)
We calculated the incremental cost effectiveness ratio for each
scenario, compared to the next-best option as measured by thePlease cite this article as: B. L. Hagedorn, J. Gauld, N. Feasey et al., Cost-effect
conjugate vaccine, Vaccine, https://doi.org/10.1016/j.vaccine.2019.12.061simulated number of acute typhoid cases. Considering only pro-
grammatic costs, the ICER for adding environmental surveillance
and the resulting catch-up campaign ranged from $66.11-
$4161.25 per case avoided. The ICER was similar but lower for totaliveness of using environmental surveillance to target the roll-out typhoid
Fig. 7. Sensitivity analysis results. The modified total societal costs are calculated by multiplying the unit cost, price, or value of the cost model parameter by 50% and then by
200% in order to assess the impact of parameter uncertainty. The net impact is the modified cost, less the original estimate. All values reported in thousands of 2018 US
dollars. Treat = treatment cost. Sev = severe. MDR = multi-drug resistant. SIA = supplementary immunization campaign. RI = routine immunization. Typ = typical (non-MDR).
ES = environmental surveillance. Unc = uncomplicated.
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$4183.57 per case avoided. (Table 2.) As the number of cases
declined, so did the proportion of costs that are due to treatment
of acute cases.
There is inherent uncertainty in relying on point estimates for
any cost value in an economic analysis and this is particularly true
for a new vaccine, aimed at a global market that only just now
being introduced. We conducted a one-way sensitivity analysis
to assess the impact of the individual parameters on the total cost
estimate and find that the price of the vaccine itself, the cost of
treatment for severe MDR cases, and the cost of vaccine delivery
are the parameters with the most impact. (Fig. 7).
4. Discussion
In this simulation study, we found that typhoid ES-based catch-
up TCV vaccination campaigns are beneficial for efficiently reduc-
ing the incidence of typhoid in a population as a supplement to
introduction of routine immunization. When compared to only
routine immunization, catch-up campaigns are a low-cost strategy
for both national and local (sub-national) targeting decisions (ICER
as low as $42.00).
A strategy that relies on a national campaign is highly respon-
sive to surveillance and results in the decision to vaccinate the
entire country in most simulation runs, especially where there is
high surveillance coverage. In fact, ES adds a minimal value if the
catch-up decision is going to be made at the national level, espe-
cially if there are high levels of underlying endemicity. However,
in the absence of blood culture-based surveillance, it remains a
critical trigger to access funds to deploy TCV at all. This leads us
to conclude that while ES is helpful, if a country had evidence that
there is endemicity in some part of the country (e.g. from a sentinel
site), then ES may not be necessary – and in fact, basing a catch-up
campaign on positive ES creates a risk for missed opportunities in
cases where ES results in a false negative.Please cite this article as: B. L. Hagedorn, J. Gauld, N. Feasey et al., Cost-effect
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evidence of widespread disease transmission exists (whether from
ES or other sources), a national catch-up campaign will minimize
missed opportunities. However, with a national campaign strategy,
there is a high probability of vaccination of low-risk populations.
This increases the ICER, but not enough to discourage a national
campaign in the absence of surveillance data.
A local strategy is more cost-effective per case avoided (see
Table 2 for ICER values), compared to a national strategy. This is
because there is a lower probability of unnecessarily vaccinating
low-risk populations. However, there is a much higher risk of
missed opportunities, since incomplete surveillance coverage
results directly in cases that could have been avoided by vaccina-
tion. Thus, local vaccination strategies are preferable to national
strategies from a cost-effectiveness perspective, if high quality
and high coverage levels of typhoid ES can be achieved. In a situa-
tion with underlying endemicity in only a few places, only those
high-risk individuals would be vaccinated, avoiding costs from a
non-endemic campaign based on a relatively small investment in
ES. In contrast, if there is high endemicity, very high coverage of
ES is required to ensure that no local transmission is overlooked.
Regardless of the scale of response (national or local), ES roll-
out would require careful planning in order to ensure adequate
coverage of the transmission locales, reflected in our finding that
the incremental portion of the population covered by ES was a sig-
nificant driver of disease burden and cost for both national and
local (sub-national) strategies. This finding is robust across scenar-
ios, as long as the test itself is a reliable indicator of underlying
transmission.
As we report in Fig. 5, ‘non-endemic vaccination’ resulted in a
higher programmatic cost per case avoided because vaccine was
given to those who were at a very low risk of infection. In contrast,
scenarios with high levels of ‘missed opportunities’ result in lower
cost-effectiveness, because there are many cases that could have
been avoided for a low vaccination cost.iveness of using environmental surveillance to target the roll-out typhoid
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the context of country-level decision making, the results are not
dependent on the size of the population. Transmission locales could
easily be defined on different scales: neighborhoods, cities, states,
countries, or even regions, though assumptions around migration
or incidence heterogeneity may alter the results somewhat.
There are several limitations to the conclusions from this study.
The most important is that the method to detect typhoid via envi-
ronmental surveillance is still in development, which creates sub-
stantial uncertainty around the true test sensitivity and cost once it
has been finalized. There is a potential to infer prevalence from ES
samples, and the methods have been developed for polio ES [10],
particularly during the Israeli outbreak of 2013 [11], but the oper-
ational and scientific feasibility of this for typhoid has not been
proven. Additionally, we assumed that ES could be placed effi-
ciently to test a concentrated water or sewer source, but this
may not always be possible, which would require duplicative sites.
This is somewhat mitigated by the fact that ES would be a rela-
tively small proportion of the total cost of typhoid control, but fur-
ther refinement of the ICER estimates would be useful once testing
and deployment methods have been further refined; once that has
been done, the ICER should be compared to a willingness-to-pay
threshold to determine whether it is a cost-effective intervention.
We also assumed that a routine immunization program would be
rolled out in all scenarios (except baseline) and calculated ICERs
including those costs. While it is unusual to do a mass vaccination
campaign in the absence of routine immunization, it is possible
that a country would opt for this strategy. However, this would
likely further reduce the ICER, so it is not a significant concern
for our conclusions. Another limitation is that our model relies
on data from a single sentinel site in Blantyre, which may or may
not represent the force of infection or seasonality found in the rest
of the country. Finally, this study makes assumptions of both geo-
graphic and temporal stability in incidence for the purposes of
evaluating a one-time tool, despite the rapid increase of typhoid
fever in Blantyre. Incorporating data that spans multiple locations
and including variability over time to further evaluate ES in chang-
ing incidence landscapes would be beneficial. Including high
migration rates between the transmission locales in the model
would almost certainly favor a national vaccination strategy,
regardless of ES detection. It should be noted that migration should
be considered when evaluating strategies in settings with rapid
emergence and spread of typhoid fever, like what has been
observed with extensively drug-resistant (XDR) typhoid in Pak-
istan [32]. Nonetheless, even in these high migration settings, ES
may be a useful tool for prioritizing locations when vaccine
resources are limited, in the absence of clinical surveillance.
This study highlights the use-case of environmental surveil-
lance in the context of vaccination decision-making for typhoid
conjugate vaccines and offers a flexible framework for additional
scenarios. For example, alternate and more complex decision-
making strategies, such as such as altering the number and portion
of positive samples required to make a decision, consideration of
migration patterns and its effect on risk of introduction, and the
use of quantitative PCR that could support more nuanced targeting.
In the absence of blood culture surveillance in many locations,
countries may be limited in their ability to utilize this vaccine
without novel methods of rapid evaluation. Beyond ES as a one-
time evaluative tool, there is additionally an opportunity to explore
the costs of using ES for ongoing monitoring and outbreak detec-
tion due to reintroduction. These findings highlight a need for
understanding the limitations of detection of typhoid ES, and the
potential for other rapid diagnostics or evaluation strategies to
aid in decision-making. Overall, we find that time-limited environ-
mental surveillance can be a cost-effective tool to support decision
making and improve targeting for catch-up vaccination campaigns.Please cite this article as: B. L. Hagedorn, J. Gauld, N. Feasey et al., Cost-effect
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